Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) major shareholder Perceptive Advisors Llc bought 2,353,000 shares of the firm's stock in a transaction that occurred on Thursday, April 11th. The shares were acquired at an average cost of $8.50 per share, with a total value of $20,000,500.00. Following the purchase, the insider now directly owns 5,360,858 shares of the company's stock, valued at $45,567,293. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Acrivon Therapeutics Stock Down 3.8 %
ACRV stock opened at $9.61 on Tuesday. Acrivon Therapeutics, Inc. has a twelve month low of $3.19 and a twelve month high of $14.30. The stock's 50 day moving average is $5.60 and its 200-day moving average is $5.24. The firm has a market capitalization of $217.57 million, a PE ratio of -3.52 and a beta of 1.93.
Wall Street Analyst Weigh In
Several research firms recently commented on ACRV. JMP Securities reaffirmed a "market outperform" rating and set a $14.00 target price on shares of Acrivon Therapeutics in a research note on Monday, April 1st. LADENBURG THALM/SH SH cut their price target on Acrivon Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, April 5th. BMO Capital Markets reiterated an "outperform" rating and issued a $18.00 price target on shares of Acrivon Therapeutics in a report on Monday, April 1st. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Acrivon Therapeutics in a report on Thursday, March 28th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Acrivon Therapeutics presently has an average rating of "Buy" and a consensus price target of $20.14.
The biggest energy story ever?
From Porter & Company | Ad
Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…
For the full story, click here.
Get Our Latest Analysis on ACRV
Institutional Trading of Acrivon Therapeutics
A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its holdings in Acrivon Therapeutics by 108.1% during the second quarter. Wells Fargo & Company MN now owns 3,305 shares of the company's stock worth $43,000 after acquiring an additional 1,717 shares during the period. Bank of New York Mellon Corp lifted its holdings in Acrivon Therapeutics by 8.6% during the second quarter. Bank of New York Mellon Corp now owns 24,795 shares of the company's stock worth $321,000 after acquiring an additional 1,958 shares during the period. New York State Common Retirement Fund bought a new stake in Acrivon Therapeutics during the first quarter worth $28,000. Citigroup Inc. lifted its holdings in Acrivon Therapeutics by 1,281.2% during the second quarter. Citigroup Inc. now owns 2,790 shares of the company's stock worth $36,000 after acquiring an additional 2,588 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Acrivon Therapeutics by 4.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 60,958 shares of the company's stock worth $790,000 after acquiring an additional 2,749 shares during the period. 71.62% of the stock is currently owned by institutional investors.
About Acrivon Therapeutics
(
Get Free Report)
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
